Blogs
Breville Group (ASX: BRG): Premium Coffee Growth, Global Expansion & AI-Driven Efficiency
Breville is a premium global small‑appliances brand leveraging coffee leadership, innovation and an asset‑light model to drive ~10% growth. Strong cash flow, balance sheet improvement and a growing Beanz ecosystem support a justified valuation premium despite tariff pressure.
Nanoveu (ASX: NVU) is at risk of breaching a critical support level. How much lower can its share price go?
Nanoveu (ASX: NVU) is a deep-tech Australian company pivoting toward ultra-low-power edge AI chips, but it remains under pressure from tiny revenue, ongoing losses, dilution, and competitive risks. Technically, the stock is testing support near 0.050, with 0.040 as the next key level if selling continues.
Anson Resources (ASX: ASN) Rebounds with Strong Upside as Investors React to Major Project Upgrade
Anson Resources rebounded near A$0.05 after a 650% resource upgrade at Green River, boosting investor sentiment. Still in development, it targets U.S. lithium supply, but remains high-risk, with weak technicals and key support at A$0.045.
Will Elixir Energy (ASX: EXR) break through a key resistance level, or is a near-term pullback ahead?
Elixir Energy (ASX: EXR) is advancing gas projects toward 2027 production, but its share price faces pressure from dilution, cash burn, and operational risks. Technically, the stock sits near key support, with momentum neutral and direction dependent on whether it holds support or breaks resistance.
How much lower can the breakdown in Appen (ASX: APX) take the share price?
Appen shares have broken down on weak fundamentals despite AI exposure, with downside risks toward ~A$1. While the business pivots to generative AI, declining core revenue and profitability issues keep it a fragile turnaround rather than a confirmed recovery story.
EchoIQ (ASX: EIQ) Surges to Record Highs as Share Price Momentum Accelerates
EchoIQ (ASX: EIQ) has surged on AI-driven healthcare momentum and US expansion, backed by strong clinical results and partnerships. While technically bullish, the stock is consolidating after a sharp rally, with key support at $0.92–$0.95 and resistance near $1.00.
Hot Chili (ASX: HCH) Rebounds as Share Price Climbs on Strong Copper-Gold Momentum
Hot Chili Ltd shares are rising on strong Chilean drilling results and growing copper demand. Its Costa Fuego project and water infrastructure position the company as an emerging, strategically important copper-gold producer.
Boss Energy Ltd (ASX: BOE): Uranium Leverage Play at the Edge of Production Breakthrough
Boss Energy (ASX: BOE) is a uranium producer ramping up the Honeymoon Project toward ~2.4M lbs annual output. Earnings are highly leveraged to uranium prices and execution, with profitability expected as production scales, despite near-term volatility, cost pressures, and ramp-up risk.
Is the market finally starting to price in a recovery for Strike Energy (ASX: STX)?
Strike Energy Limited is a Perth Basin gas producer transitioning into gas-to-power and new energy. Improving reserves, project progress, and stronger pricing may signal a recovery, while shares rebound from long-term lows as momentum strengthens.
European Lithium (ASX: EUR) has reached our target price already! Here's what happened.
European Lithium (ASX: EUR) hit its target price after a high-volume breakout from consolidation, rallying to A$0.39. A proposed US$835M acquisition by Critical Metals Corp and renewed interest in its lithium and rare earth assets drove the surge.
Encounter Resources’ (ASX: ENR) share price is showing signs of a reversal
Encounter Resources (ASX: ENR) is an Australian mineral explorer targeting copper and critical minerals. Backed by solid funding and major partnerships, its share price exhibits bullish reversal signs, though future growth relies heavily on successful high-grade exploration discoveries.
What is the reason for the plummet in Dimerix (ASX: DXB) share price, and how much lower can it go?
Dimerix shares plunged 35–40% amid heavy selling and uncertainty around clinical updates, worsened by weak biotech sentiment. Further downside depends on results and the funding outlook, though volatility in early-stage biotech stocks suggests a potential for sharp rebounds.
Our 3 high-conviction ASX income stocks for 2026
This report highlights three high-yield ASX dividend stocks across different industries, offering strong income and upside potential over the next 6–12 months, backed by durable competitive advantages, profitable business models, and valuations that appear attractive relative to their long-term growth prospects.
Has Nuix's (ASX: NXL) share price formed a base? What is the chart signalling?
Nuix remains in a weak downtrend despite a bounce toward ~$1.5. The stock is consolidating between ~$1.1–$1.5, showing stabilisation but no confirmed bottom. A breakout above resistance is needed, with risks still skewed to the downside.
How much higher can Lodestar Minerals' (ASX: LSR) share price go after the recent breakout?
Lodestar Minerals has surged ~129% YTD after a breakout to ~$0.028, with potential upside toward $0.03–$0.04 if momentum continues. However, as an early-stage explorer, gains are likely event-driven and volatile, with sustainability dependent on exploration success.
Lynas Rare Earths (ASX: LYC) breaks its short term uptrend — how much lower can its share price go?
Lynas Rare Earths (ASX: LYC) recently broke its short-term uptrend due to weak Q3 production, facility outages, and expansion costs. Technical analysis indicates strong downside momentum, with the next major support zone sitting lower around the $16.00–$16.23 level.
Meeka Metals (ASX: MEK) Tests Major Support: Can the Downtrend Stabilise?
Meeka Metals faces selling pressure near key support after a volatile year, amid operational challenges and cautious sentiment. As it transitions to production at Murchison, investors are watching whether support holds or signals further downside despite long-term growth potential.
Is Orthocell's (ASX: OCC) Recent Share Price Decline a Warning Sign or a Buying Signal?
Orthocell is a regenerative medicine company expanding Remplir globally, but investors remain cautious because revenue growth is uneven, the business is still loss-making, and U.S. uptake may take time, leaving the stock a higher-risk turnaround opportunity.
With signs of a trend reversal emerging in Treasury Wine Estates (ASX: TWE) shares, what could be the next upside target?
Treasury Wine Estates shows early reversal signs after a downturn, supported by restructuring optimism and stabilising demand. Key upside lies around A$5.30–A$5.70, with further gains possible if momentum holds, though sustained strength is needed to confirm a broader recovery.
Why Cochlear's (ASX: COH) share price keeps crashing, and where can it find a bottom?
Cochlear’s share price slump reflects profit downgrades, slowing growth, weak global demand, and macro pressures. The stock is down sharply, but a lasting bottom likely depends on stabilising earnings and clearer signs of demand recovery.
